These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9493137)

  • 1. Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B.
    Clamon G; Herndon J; Akerley W; Green M
    Lung Cancer; 1998 Jan; 19(1):25-9. PubMed ID: 9493137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B.
    Clamon G; Herndon J; Perry MC; Ozer H; Kreisman H; Maher T; Ellerton J; Green MR
    J Natl Cancer Inst; 1993 Feb; 85(4):316-20. PubMed ID: 8381188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).
    Luikart SD; Herndon JE; Hollis DR; MacDonald M; Maurer LH; Crawford J; Clamon GH; Wright J; Perry MC; Ozer H; Green MR
    Am J Clin Oncol; 1997 Feb; 20(1):24-30. PubMed ID: 9020283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study.
    Mitchell EP; Perry MC; Luikart SD; Cirrincione CT; Van Echo DA; Herndon JE; Maurer LH; Clamon G; Green MR
    Lung Cancer; 1996 Sep; 15(2):215-23. PubMed ID: 8882988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
    Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
    J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
    Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of etoposide and cisplatin for refractory small cell lung cancer: a Cancer and Leukemia Group B Study.
    Graziano SL; Lee K; Propert KJ; Tinsley R; Hayes DM; Green M; Comis RL
    Med Pediatr Oncol; 1990; 18(1):22-6. PubMed ID: 2152956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
    Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235).
    McClay EF; Bogart J; Herndon JE; Watson D; Evans L; Seagren SL; Green MR;
    Am J Clin Oncol; 2005 Feb; 28(1):81-90. PubMed ID: 15685040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose-intense chemotherapy alone or in combination with interleukin-2 for small cell lung cancer: a pilot study.
    Pollera CF; Calabresi F; Moreschi M; Ruggeri EM; Giannarelli D; Masciulli R; Testa U; Peschle C
    Cancer Invest; 1994; 12(6):574-87. PubMed ID: 7994592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
    Hainsworth JD; Greco FA
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of etoposide and carboplatin in extensive small-cell lung cancer. A report from the Cancer and Leukemia Group B.
    Luikart SD; Goutsou M; Mitchell ED; Van Echo DA; Modeas CR; Propert KJ; O'Donnell J; Difino S; Perry MC; Green MR
    Am J Clin Oncol; 1993 Apr; 16(2):127-31. PubMed ID: 8383914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
    Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
    Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
    Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
    Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
    Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S
    Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer.
    Murphy PB; Hainsworth JD; Greco FA; Hande KR; DeVore RF; Johnson DH
    Cancer; 1992 Jan; 69(2):370-5. PubMed ID: 1309432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.
    Girling DJ
    Lancet; 1996 Aug; 348(9027):563-6. PubMed ID: 8774567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.
    Dowlati A; Crosby L; Remick SC; Makkar V; Levitan N
    Lung Cancer; 2001 May; 32(2):155-62. PubMed ID: 11325486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.